Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients

International Journal of Cancer

Volumn 79, Issue 3, 1998, Pages 241-244

  Tempfer, Clemens ^a   Hefler, Lukas ^a   Haeusler, Guenther ^a   Reinthaller, Alexander ^a   Koelbl, Heinz ^a   Zeisler, Harald ^a   Kainz, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOHYDRATE ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CARCINOMA, SQUAMOUS CELL; EVALUATION STUDIES; FEMALE; HUMANS; OVARIAN NEOPLASMS; PEPTIDES; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0031799457     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980619)79:3<241::AID-IJC5>3.0.CO;2-P     Document Type: Article

References (28)

1. BANFI, G., ZERBI, A., PASTORI, S., PAROLINI, D., DI CARLO, V. and BONINI, P., Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin. Chem., 39, 420-423 (1993).
2. BJORKLUND, B., LUNDBLAD, G. and BJORKLUND, V., Amigenicity of pooled human malignant and normal tissues by cytoimmunological technique. II. Nature of tumor antigen. Int. Arch. Allergy, 12, 241-261 (1958).
3. BONFRER, J.M., GROENEVELD, E.M., KORSE, C.M., VAN DALEN, A., OOMEN, L.C. and IVANYI, D., Monoclonal antibody M3 used in tissue polypeptide specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumor Biol. 15, 210-222 (1994).
4. DEVINE, P.L., MCGUCKIN, M.A., QUIN, R.J. and WARD, B.G., Predictive value of the combination of serum markers CA 125, CASA and TPS in ovarian cancer. Int. J. Gynecol. Cancer, 5, 170-178 (1995).
5. FERDEGHINI, M., GADDUCCI, A. and PRONTERA, C., Determination of serum levels of different cytokeratins in patients with uterine malignancies. Anticancer Res., 14, 1393-1397 (1994).
6. GION, M., MIONE, R. and BECCIOLINI, A., Relationship between cytosol TPS, TPA and cell proliferation. Int. J. Biol. Markers, 9, 109-114 (1994).
7. GITSCH, G., KAINZ, C., JOURA, E., FROHLICH, B., BIEGLMAYER, C. and TATRA, G., Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptidc specific antigen in follow up of stage III cervical cancer. Anticancer Res., 12, 1247-1249 (1992).
8. HEILENKOTIER, U., JAGELLA, P., BAHLO, M. and KLAPDOR, R., TPS compared to CA 15-3 and CEA in primary diagnosis of breast cancer. In: R. Klapdor (ed.), Current tumor diagnosis: applications, clinical relevance, research, trends, pp 152-154, W. Zuekersehwerdt Munich (1994).
9. HOECKEL, M., SCHLENGHR, K., HAMM, H., KNAPSTEIN, P.G., HOHENFELLNER, R. and ROSLER, H.P., Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall. Cancer, 77, 1918-1933 (1996).
10. HOGBERG, T. and KAGEDAL, B., Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol. Oncol., 46, 191-198 (1992).
11. KLEIN, B., LURIE, H. and LEVIN, I., A comparative study of tumor markers of proliferation, differentiation and tumor immunology in breast cancer patients. Cancer J., 7, 238-240 (1994).
12. KORNEK, G., SCHENK, T., RADERER, M., DJAVARNMAND, M. and SCHEITHAUER, W., Tissue polypeptide specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumors. Brit. J. Cancer, 71, 182-185 (1995).
13. KREBS, H.B., GOPLERUD, D.R., KILPATRICK, S.J., MYERS, M.B. and HUNT, A., Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet. Gynecol., 67, 473-477 (1986).
14. MARUO, T., SHIBATA, K. and KIMURA, A., Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization. Cancer, 56, 302-308 (1985).
15. MELLERICK, D.M., OSBORN, M. and WEBER, K., On the nature of serological tissue polypeptide antigen (TPA): monoclonal keratin 8, 18 and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene, 5, 1007-1017 (1990).
16. MOLL, R., FRANKE, W.W., SCHILLER, D.L., GEIGER, B. and KREPLER, R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31, 11-24 (1982).
17. NGAN, H.Y., CHENG, G.T. and YEUNG, W.S., The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. Gynecol. Oncol., 52, 63-68 (1994).
18. PLEBANI, M., BASSO, D. and DEL FAVERO, G., Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer. Oncology, 50, 436-440 (1993).
19. ROSE, P.G., BAKER, S. and FOURNIER, L., Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Amer. J. Obstet. Gynecol., 168, 942-946 (1993).
20. SABBATINI, S., MONTI, M. and FINI, A., Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology. Int. J. Biol. Markers, 3, 127-128 (1988).
21. STIEBER, P., BODENMUELLER, H. and BANAUCH, D., Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin. Biochem., 26, 301-304 (1993).
22. STIEBER, P., DIENEMANN, H. and HASHOLZNER, U., Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int. J. Biol. Markers, 9, 82-88 (1994).
23. SUNDSTROM, B.E. and STIGBRAND, T.I., Cytokeratins and tissue polypeptide antigen. Int. J. Biol. Markers, 9, 102-108 (1994).
24. TARLE, M., FRKOVIC-GRAZIO, S., KRALJIC, I. and KOVACIC, K., A more objective staging of advanced prostate cancer-routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA and NSE values. Prostate, 24, 143-148 (1994).
25. TEMPFER, C., HANZAL, E. and ZEILLTNGER, R., The new serum tumor marker M3/M21 in the follow-up of breast cancer patients. Anticancer Res., 16, 2135-2138 (1996).
26. THIGPEN, J., VANCE, R. and KHANSUR, T., Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer, 71, 1559-1564 (1993).
27. VAN DALEN, A., VAN DER LINDE, D.L., HEERING, K.J. and BLUSSE VAN OUDALBLAS, A., How can treatment response be measured in breast cancer patients? Anticancer Res., 13, 1901-1904 (1993).
28. VAN DER GAAST, A., SCMOENMAKERS, C.H., KOK, T.C., BLIJENBERG, B.C., HOP, W.C. and SPLINTER, T.A., Prognostic significance of tissue polypeptide specific antigen (TPS) in patients with advanced non-small cell lung cancer. Europ. J. Cancer, 30, 1783-1786 (1994).